Serious adverse events
|
20120229 / 20120230 Placebo |
20120229 / 20120230 Etelcalcetide |
20120359 Etelcalcetide |
Total |
Total subjects affected by serious adverse events
|
|
|
|
|
subjects affected / exposed
|
161 / 383 (42.04%) |
142 / 384 (36.98%) |
53 / 123 (43.09%) |
356 / 890 (40.00%) |
number of deaths (all causes)
|
27 |
16 |
8 |
51 |
number of deaths resulting from adverse events
|
|
|
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
|
|
|
|
Adenocarcinoma of colon
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bladder adenocarcinoma stage unspecified
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Breast cancer
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Clear cell renal cell carcinoma
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Colon cancer stage II
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lung cancer metastatic
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Metastases to spine
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Neoplasm malignant
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
Pancreatic carcinoma
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Prostate cancer
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sarcoma
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Squamous cell carcinoma of skin
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Thyroid neoplasm
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vascular disorders
|
|
|
|
|
Aortic aneurysm
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Aortic stenosis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Arterial occlusive disease
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Deep vein thrombosis
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dry gangrene
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Extremity necrosis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haematoma
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypertension
|
|
|
|
|
subjects affected / exposed
|
5 / 383 (1.31%) |
4 / 384 (1.04%) |
1 / 123 (0.81%) |
10 / 890 (1.12%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
0 / 1 |
0 / 11 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypertensive crisis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypertensive emergency
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypotension
|
|
|
|
|
subjects affected / exposed
|
5 / 383 (1.31%) |
4 / 384 (1.04%) |
2 / 123 (1.63%) |
11 / 890 (1.24%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 4 |
0 / 2 |
0 / 11 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Jugular vein thrombosis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Malignant hypertension
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Orthostatic hypotension
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral arterial occlusive disease
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 2 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral vascular disorder
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
4 / 384 (1.04%) |
0 / 123 (0.00%) |
6 / 890 (0.67%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 4 |
0 / 0 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
Shock haemorrhagic
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Steal syndrome
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vasculitis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Surgical and medical procedures
|
|
|
|
|
Arteriovenous graft
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Therapy cessation
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
General disorders and administration site conditions
|
|
|
|
|
Adverse drug reaction
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Asthenia
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
2 / 384 (0.52%) |
1 / 123 (0.81%) |
5 / 890 (0.56%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 1 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Chest pain
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
7 / 384 (1.82%) |
1 / 123 (0.81%) |
11 / 890 (1.24%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 8 |
0 / 1 |
0 / 12 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Device occlusion
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Drug resistance
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhagic cyst
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hyperthermia
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hyperthermia malignant
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypothermia
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Impaired healing
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Non-cardiac chest pain
|
|
|
|
|
subjects affected / exposed
|
6 / 383 (1.57%) |
5 / 384 (1.30%) |
1 / 123 (0.81%) |
12 / 890 (1.35%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 5 |
0 / 2 |
0 / 13 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pyrexia
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
2 / 384 (0.52%) |
3 / 123 (2.44%) |
7 / 890 (0.79%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 3 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sudden death
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 3 |
Thrombosis in device
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
2 / 123 (1.63%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 2 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Immune system disorders
|
|
|
|
|
Drug hypersensitivity
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypersensitivity
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Seasonal allergy
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Reproductive system and breast disorders
|
|
|
|
|
Benign prostatic hyperplasia
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Menorrhagia
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pelvic haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Postmenopausal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory, thoracic and mediastinal disorders
|
|
|
|
|
Acute pulmonary oedema
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Acute respiratory failure
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
Aspiration
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Asthma
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bronchospasm
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Chronic obstructive pulmonary disease
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cough
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dyspnoea
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
3 / 384 (0.78%) |
1 / 123 (0.81%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 3 |
0 / 1 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dyspnoea exertional
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Epistaxis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 1 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypoxia
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pleural effusion
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia aspiration
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary cavitation
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary congestion
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary embolism
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
2 / 384 (0.52%) |
1 / 123 (0.81%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
Pulmonary infarction
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary mass
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pulmonary oedema
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
3 / 384 (0.78%) |
0 / 123 (0.00%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 0 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory arrest
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory failure
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
5 / 890 (0.56%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
0 / 0 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Stridor
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Throat tightness
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Psychiatric disorders
|
|
|
|
|
Confusional state
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Delirium
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Depression
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
2 / 384 (0.52%) |
1 / 123 (0.81%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Depression suicidal
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hallucination, visual
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Mental status changes
|
|
|
|
|
subjects affected / exposed
|
6 / 383 (1.57%) |
0 / 384 (0.00%) |
2 / 123 (1.63%) |
8 / 890 (0.90%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 0 |
0 / 2 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Investigations
|
|
|
|
|
Alanine aminotransferase increased
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Anticoagulation drug level below therapeutic
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Aspartate aminotransferase increased
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
1 / 2 |
0 / 0 |
0 / 0 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bilirubin conjugated increased
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Blood alkaline phosphatase increased
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Blood bilirubin increased
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Blood calcium decreased
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Blood pressure increased
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatitis C antibody positive
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
International normalised ratio increased
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Troponin increased
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Weight decreased
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Injury, poisoning and procedural complications
|
|
|
|
|
Ankle fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Arteriovenous fistula occlusion
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Arteriovenous fistula site complication
|
|
|
|
|
subjects affected / exposed
|
7 / 383 (1.83%) |
6 / 384 (1.56%) |
0 / 123 (0.00%) |
13 / 890 (1.46%) |
occurrences causally related to treatment / all
|
0 / 11 |
0 / 6 |
0 / 0 |
0 / 17 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Arteriovenous fistula site haemorrhage
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
4 / 384 (1.04%) |
1 / 123 (0.81%) |
8 / 890 (0.90%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 7 |
0 / 1 |
0 / 11 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Arteriovenous fistula thrombosis
|
|
|
|
|
subjects affected / exposed
|
4 / 383 (1.04%) |
6 / 384 (1.56%) |
0 / 123 (0.00%) |
10 / 890 (1.12%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 9 |
0 / 0 |
0 / 15 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cervical vertebral fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Clavicle fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Complications of transplanted kidney
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Compression fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Contusion
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Coronary bypass thrombosis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dialysis related complication
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Facial bones fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Fall
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
2 / 384 (0.52%) |
1 / 123 (0.81%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Femoral neck fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Femur fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Foot fracture
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Graft thrombosis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemodialysis-induced symptom
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
1 / 1 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hip fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Humerus fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intentional overdose
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Jaw fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lower limb fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lumbar vertebral fracture
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Multiple fractures
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Patella fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Peripheral arterial reocclusion
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Perirenal haematoma
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Post procedural complication
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Post procedural haematoma
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Postoperative respiratory failure
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Procedural hypotension
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Radius fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 2 |
0 / 0 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Shunt stenosis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Shunt thrombosis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Soft tissue injury
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Splenic injury
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Stoma site pain
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Subdural haematoma
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Thermal burn
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tibia fracture
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Toxicity to various agents
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vascular access complication
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vascular graft complication
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
2 / 384 (0.52%) |
2 / 123 (1.63%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 3 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vascular graft thrombosis
|
|
|
|
|
subjects affected / exposed
|
4 / 383 (1.04%) |
2 / 384 (0.52%) |
2 / 123 (1.63%) |
8 / 890 (0.90%) |
occurrences causally related to treatment / all
|
0 / 9 |
0 / 2 |
0 / 3 |
0 / 14 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vascular pseudoaneurysm
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Wound
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Wound complication
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Wound dehiscence
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Wound haemorrhage
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac disorders
|
|
|
|
|
Acute coronary syndrome
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 1 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Acute myocardial infarction
|
|
|
|
|
subjects affected / exposed
|
5 / 383 (1.31%) |
6 / 384 (1.56%) |
0 / 123 (0.00%) |
11 / 890 (1.24%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 7 |
0 / 0 |
0 / 12 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
Angina pectoris
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
3 / 384 (0.78%) |
2 / 123 (1.63%) |
7 / 890 (0.79%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 3 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Angina unstable
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Aortic valve disease
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Aortic valve incompetence
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Aortic valve stenosis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Arrhythmia
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Atrial fibrillation
|
|
|
|
|
subjects affected / exposed
|
9 / 383 (2.35%) |
4 / 384 (1.04%) |
0 / 123 (0.00%) |
13 / 890 (1.46%) |
occurrences causally related to treatment / all
|
0 / 12 |
0 / 4 |
0 / 0 |
0 / 16 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Atrial flutter
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Atrioventricular block complete
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bradycardia
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
2 / 384 (0.52%) |
1 / 123 (0.81%) |
5 / 890 (0.56%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 3 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac arrest
|
|
|
|
|
subjects affected / exposed
|
6 / 383 (1.57%) |
2 / 384 (0.52%) |
4 / 123 (3.25%) |
12 / 890 (1.35%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 2 |
0 / 4 |
0 / 12 |
deaths causally related to treatment / all
|
0 / 3 |
0 / 2 |
0 / 4 |
0 / 9 |
Cardiac disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Cardiac failure
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
3 / 384 (0.78%) |
0 / 123 (0.00%) |
5 / 890 (0.56%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 0 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
Cardiac failure acute
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
Cardiac failure chronic
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiac failure congestive
|
|
|
|
|
subjects affected / exposed
|
8 / 383 (2.09%) |
7 / 384 (1.82%) |
3 / 123 (2.44%) |
18 / 890 (2.02%) |
occurrences causally related to treatment / all
|
0 / 11 |
0 / 7 |
0 / 5 |
0 / 23 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Cardiac valve disease
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardio-respiratory arrest
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
3 / 384 (0.78%) |
0 / 123 (0.00%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 0 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 3 |
0 / 0 |
0 / 3 |
Cardiogenic shock
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Cardiomyopathy
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cardiovascular insufficiency
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Coronary artery disease
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
6 / 384 (1.56%) |
0 / 123 (0.00%) |
9 / 890 (1.01%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 6 |
0 / 0 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Coronary artery stenosis
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Mitral valve incompetence
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Myocardial infarction
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
4 / 384 (1.04%) |
1 / 123 (0.81%) |
7 / 890 (0.79%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 5 |
0 / 1 |
0 / 8 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Myocardial ischaemia
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Palpitations
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pericardial effusion
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sinus node dysfunction
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 2 |
0 / 0 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Supraventricular tachycardia
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tachycardia
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Torsade de pointes
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tricuspid valve incompetence
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ventricular fibrillation
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
2 / 384 (0.52%) |
2 / 123 (1.63%) |
6 / 890 (0.67%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 2 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 3 |
Nervous system disorders
|
|
|
|
|
Altered state of consciousness
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ataxia
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Carotid artery stenosis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cerebral haemorrhage
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Cerebral infarction
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cerebrovascular accident
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 0 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dizziness
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Encephalopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
3 / 384 (0.78%) |
1 / 123 (0.81%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 4 |
0 / 1 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Generalised tonic-clonic seizure
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhage intracranial
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Headache
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hemiparesis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypoaesthesia
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypoxic-ischaemic encephalopathy
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Loss of consciousness
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Meralgia paraesthetica
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metabolic encephalopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Migraine
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Presyncope
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Seizure
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
1 / 3 |
0 / 1 |
0 / 0 |
1 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Subarachnoid haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Syncope
|
|
|
|
|
subjects affected / exposed
|
6 / 383 (1.57%) |
2 / 384 (0.52%) |
3 / 123 (2.44%) |
11 / 890 (1.24%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 2 |
0 / 3 |
0 / 11 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Transient ischaemic attack
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tremor
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Blood and lymphatic system disorders
|
|
|
|
|
Anaemia
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
1 / 384 (0.26%) |
2 / 123 (1.63%) |
6 / 890 (0.67%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
0 / 3 |
0 / 9 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Anaemia of chronic disease
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhagic anaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Leukocytosis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lymphadenopathy
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Nephrogenic anaemia
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Thrombocytopenia
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ear and labyrinth disorders
|
|
|
|
|
Deafness neurosensory
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vertigo
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Eye disorders
|
|
|
|
|
Cataract
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diplopia
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lens dislocation
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Optic neuropathy
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal disorders
|
|
|
|
|
Abdominal adhesions
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal pain
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
3 / 384 (0.78%) |
1 / 123 (0.81%) |
7 / 890 (0.79%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 3 |
0 / 1 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal pain lower
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal pain upper
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Abdominal wall haematoma
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Anorectal varices haemorrhage
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ascites
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Colitis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Colitis ischaemic
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Constipation
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Dental caries
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic gastroparesis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 2 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diarrhoea
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diverticular perforation
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diverticulum intestinal
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Duodenal ulcer
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Enteritis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Enterocutaneous fistula
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastric antral vascular ectasia
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastric disorder
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastric haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastritis
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastritis erosive
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastritis haemorrhagic
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
2 / 123 (1.63%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 2 |
1 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
4 / 384 (1.04%) |
4 / 123 (3.25%) |
10 / 890 (1.12%) |
occurrences causally related to treatment / all
|
0 / 4 |
0 / 6 |
0 / 4 |
0 / 14 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal necrosis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastrointestinal vascular malformation
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastrooesophageal reflux disease
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haematemesis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhoidal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haemorrhoids
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Ileus
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Inguinal hernia
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intestinal ischaemia
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intestinal perforation
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Large intestine perforation
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Large intestine polyp
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Megacolon
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Nausea
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Oesophagitis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatic duct obstruction
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatitis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pancreatitis acute
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rectal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Small intestinal obstruction
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
2 / 384 (0.52%) |
1 / 123 (0.81%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 4 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Subileus
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Upper gastrointestinal haemorrhage
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vomiting
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
5 / 890 (0.56%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 1 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatobiliary disorders
|
|
|
|
|
Bile duct stone
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Biliary colic
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cholangitis acute
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cholecystitis
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
3 / 384 (0.78%) |
0 / 123 (0.00%) |
5 / 890 (0.56%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 3 |
0 / 0 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cholelithiasis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatic cirrhosis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatitis acute
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hepatotoxicity
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Skin and subcutaneous tissue disorders
|
|
|
|
|
Angioedema
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Decubitus ulcer
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic foot
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
2 / 384 (0.52%) |
2 / 123 (1.63%) |
5 / 890 (0.56%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 4 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Henoch-Schonlein purpura
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
1 / 1 |
0 / 0 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Purpura
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Skin ulcer
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
5 / 384 (1.30%) |
0 / 123 (0.00%) |
6 / 890 (0.67%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 6 |
0 / 0 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Vasculitic rash
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal and urinary disorders
|
|
|
|
|
Azotaemia
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 2 |
0 / 0 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Chronic kidney disease
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Haematuria
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Nephrolithiasis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Nephrosclerosis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal colic
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal cyst haemorrhage
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal impairment
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Endocrine disorders
|
|
|
|
|
Goitre
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Musculoskeletal and connective tissue disorders
|
|
|
|
|
Arthralgia
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 1 |
1 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Arthritis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bone pain
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bursitis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Flank pain
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Joint swelling
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Musculoskeletal chest pain
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Musculoskeletal pain
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Neuropathic arthropathy
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Osteoarthritis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pain in extremity
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rhabdomyolysis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Rotator cuff syndrome
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Spinal osteoarthritis
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Spinal pain
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Infections and infestations
|
|
|
|
|
Abdominal wall abscess
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Abscess limb
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Acinetobacter bacteraemia
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Acinetobacter infection
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Appendicitis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Arteriovenous graft site infection
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
2 / 123 (1.63%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 3 |
0 / 2 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bacteraemia
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 2 |
0 / 0 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bacterial sepsis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bacterial tracheitis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bronchitis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Bronchopneumonia
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
Campylobacter gastroenteritis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cellulitis
|
|
|
|
|
subjects affected / exposed
|
8 / 383 (2.09%) |
4 / 384 (1.04%) |
1 / 123 (0.81%) |
13 / 890 (1.46%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 5 |
0 / 1 |
0 / 14 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Clostridium difficile colitis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Clostridium difficile infection
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Cystitis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Device related infection
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 0 |
0 / 1 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Device related sepsis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic gangrene
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diverticulitis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Endocarditis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Enteritis infectious
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Erysipelas
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Escherichia bacteraemia
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gangrene
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
2 / 123 (1.63%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 4 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis
|
|
|
|
|
subjects affected / exposed
|
6 / 383 (1.57%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
6 / 890 (0.67%) |
occurrences causally related to treatment / all
|
0 / 7 |
0 / 0 |
0 / 0 |
0 / 7 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Gastroenteritis viral
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Genital abscess
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Graft infection
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 1 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Helicobacter gastritis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Herpes zoster
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Infected skin ulcer
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 0 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Infectious mononucleosis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Influenza
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
1 / 384 (0.26%) |
2 / 123 (1.63%) |
6 / 890 (0.67%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 2 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Intervertebral discitis
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Localised infection
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Lower respiratory tract infection
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Osteomyelitis
|
|
|
|
|
subjects affected / exposed
|
4 / 383 (1.04%) |
3 / 384 (0.78%) |
1 / 123 (0.81%) |
8 / 890 (0.90%) |
occurrences causally related to treatment / all
|
0 / 6 |
0 / 3 |
0 / 1 |
0 / 10 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Osteomyelitis acute
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Perirectal abscess
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Peritonitis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia
|
|
|
|
|
subjects affected / exposed
|
7 / 383 (1.83%) |
5 / 384 (1.30%) |
3 / 123 (2.44%) |
15 / 890 (1.69%) |
occurrences causally related to treatment / all
|
0 / 8 |
0 / 6 |
0 / 3 |
0 / 17 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Pneumonia bacterial
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Postoperative wound infection
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Renal cyst infection
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Respiratory tract infection
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 2 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Sepsis
|
|
|
|
|
subjects affected / exposed
|
10 / 383 (2.61%) |
2 / 384 (0.52%) |
3 / 123 (2.44%) |
15 / 890 (1.69%) |
occurrences causally related to treatment / all
|
0 / 12 |
0 / 2 |
0 / 4 |
0 / 18 |
deaths causally related to treatment / all
|
0 / 2 |
0 / 1 |
0 / 0 |
0 / 3 |
Septic shock
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
1 / 384 (0.26%) |
2 / 123 (1.63%) |
6 / 890 (0.67%) |
occurrences causally related to treatment / all
|
0 / 3 |
0 / 1 |
0 / 2 |
0 / 6 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
Shunt infection
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Skin infection
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Staphylococcal bacteraemia
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
1 / 123 (0.81%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 1 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Staphylococcal sepsis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Subcutaneous abscess
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tracheitis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Tracheobronchitis
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Upper respiratory tract infection
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
1 / 123 (0.81%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 1 |
0 / 1 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Urinary tract infection
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
2 / 384 (0.52%) |
1 / 123 (0.81%) |
4 / 890 (0.45%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 1 |
0 / 4 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Urosepsis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
2 / 384 (0.52%) |
0 / 123 (0.00%) |
3 / 890 (0.34%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 4 |
0 / 0 |
0 / 5 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Viral infection
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Viral upper respiratory tract infection
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Wound infection
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Wound sepsis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
Metabolism and nutrition disorders
|
|
|
|
|
Dehydration
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diabetes mellitus
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Diabetic ketoacidosis
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 2 |
0 / 0 |
0 / 0 |
0 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Failure to thrive
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
Fluid overload
|
|
|
|
|
subjects affected / exposed
|
3 / 383 (0.78%) |
8 / 384 (2.08%) |
4 / 123 (3.25%) |
15 / 890 (1.69%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 8 |
0 / 4 |
0 / 17 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hyperkalaemia
|
|
|
|
|
subjects affected / exposed
|
14 / 383 (3.66%) |
10 / 384 (2.60%) |
5 / 123 (4.07%) |
29 / 890 (3.26%) |
occurrences causally related to treatment / all
|
0 / 14 |
0 / 11 |
0 / 7 |
0 / 32 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypervolaemia
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 2 |
0 / 0 |
0 / 3 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypocalcaemia
|
|
|
|
|
subjects affected / exposed
|
2 / 383 (0.52%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
2 / 890 (0.22%) |
occurrences causally related to treatment / all
|
2 / 2 |
0 / 0 |
0 / 0 |
2 / 2 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypoglycaemia
|
|
|
|
|
subjects affected / exposed
|
5 / 383 (1.31%) |
4 / 384 (1.04%) |
1 / 123 (0.81%) |
10 / 890 (1.12%) |
occurrences causally related to treatment / all
|
0 / 5 |
0 / 5 |
0 / 1 |
0 / 11 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Hypophosphataemia
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
1 / 1 |
0 / 0 |
1 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Malnutrition
|
|
|
|
|
subjects affected / exposed
|
1 / 383 (0.26%) |
0 / 384 (0.00%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 1 |
0 / 0 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |
Metabolic acidosis
|
|
|
|
|
subjects affected / exposed
|
0 / 383 (0.00%) |
1 / 384 (0.26%) |
0 / 123 (0.00%) |
1 / 890 (0.11%) |
occurrences causally related to treatment / all
|
0 / 0 |
0 / 1 |
0 / 0 |
0 / 1 |
deaths causally related to treatment / all
|
0 / 0 |
0 / 0 |
0 / 0 |
0 / 0 |